UK biotech sector loses flagship PowderJect to Chiron.
作者信息
Mitchell Pete
出版信息
Nat Biotechnol. 2003 Jul;21(7):717. doi: 10.1038/nbt0703-717.
PMID:12833073
Abstract
摘要
相似文献
1
UK biotech sector loses flagship PowderJect to Chiron.
Nat Biotechnol. 2003 Jul;21(7):717. doi: 10.1038/nbt0703-717.
2
Does biotech M&A benefit investors?
Nat Biotechnol. 2004 Sep;22(9):1085. doi: 10.1038/nbt0904-1085.
3
The closure of Sugen.
Nat Biotechnol. 2003 Sep;21(9):969. doi: 10.1038/nbt0903-969a.
4
Is Elan a turnaround?
Nat Biotechnol. 2003 Sep;21(9):985. doi: 10.1038/nbt0903-985.
5
Sugen falls as casualty of Pfizer-Pharmacia merger.
Nat Biotechnol. 2003 Jul;21(7):722-3. doi: 10.1038/nbt0703-722.
6
Evolving symbiosis--venture capital and biotechnology.
Nat Biotechnol. 2003 Sep;21(9):983-4. doi: 10.1038/nbt0903-983.
7
Biotechnology partnerships--medicine for an ailing industry?
Nat Biotechnol. 2003 Aug;21(8):847-8. doi: 10.1038/nbt0803-847.
8
Hyseq-Variagenics merger signals end of the line.
Nat Biotechnol. 2003 Jan;21(1):5. doi: 10.1038/nbt0103-5.
9
Splurge or merge?
Nat Biotechnol. 2003 May;21(5):485. doi: 10.1038/nbt0503-485.
10
Antiinfective biotechs face partnering gap.
Nat Biotechnol. 2005 Feb;23(2):155-6. doi: 10.1038/nbt0205-155.
Zotero 插件